Somerville Kurt F trimmed its position in Johnson & Johnson (NYSE:JNJ) by 4.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 168,146 shares of the company’s stock after selling 6,915 shares during the quarter. Johnson & Johnson comprises 4.5% of Somerville Kurt F’s holdings, making the stock its largest position. Somerville Kurt F’s holdings in Johnson & Johnson were worth $22,244,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in the company. Lenox Wealth Advisors Inc. raised its position in Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after acquiring an additional 5 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its position in Johnson & Johnson by 241.0% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after acquiring an additional 841 shares in the last quarter. Ullmann Financial Group Inc. purchased a new position in Johnson & Johnson during the first quarter valued at approximately $186,000. Taylor Wealth Management Partners raised its position in Johnson & Johnson by 19.8% during the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after acquiring an additional 250 shares in the last quarter. Finally, Puplava Financial Services Inc. purchased a new position in Johnson & Johnson during the second quarter valued at approximately $202,000. Hedge funds and other institutional investors own 65.89% of the company’s stock.
JNJ has been the subject of several recent research reports. BidaskClub cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 1st. Morgan Stanley raised their price objective on Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, July 5th. Wells Fargo & Company reissued a “market perform” rating and issued a $135.00 price objective (up from $132.00) on shares of Johnson & Johnson in a report on Thursday, July 6th. Royal Bank Of Canada reissued a “buy” rating and issued a $138.00 price objective on shares of Johnson & Johnson in a report on Wednesday, July 12th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $145.00 price objective (up from $140.00) on shares of Johnson & Johnson in a report on Friday, July 14th. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $143.70.
COPYRIGHT VIOLATION NOTICE: This report was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/10/28/johnson-johnson-jnj-shares-sold-by-somerville-kurt-f.html.
Johnson & Johnson (NYSE JNJ) traded down 0.02% during midday trading on Friday, reaching $141.78. The company’s stock had a trading volume of 5,140,654 shares. The firm has a market cap of $380.54 billion, a price-to-earnings ratio of 24.66 and a beta of 0.78. The company has a 50 day moving average price of $135.26 and a 200 day moving average price of $131.38. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $144.35.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.68%. The firm had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. During the same quarter in the prior year, the business posted $1.68 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, equities research analysts expect that Johnson & Johnson will post $7.28 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.37%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.